FDA approves 1st drug to treat postpartum depression

Postpartum depression affects as many as 400,000 women in the United States every year, and on Tuesday, the Food and Drug Administration approved the first drug specifically created to treat the disorder.
Brexanolone, also known as Zulresso, is delivered intravenously. The infusion takes 60 hours, and during a clinical trial, most participants showed improvement within 24 hours of receiving the drug, and reported they still felt the effects 30 days later. Brexanolone contains a synthetic form of allopregnanolone, a derivative of progesterone, which increases during pregnancy and drops dramatically after giving birth. It is thought allopregnanolone could contribute to postpartum depression.
Women with postpartum depression often feel profound sadness, anxiety, or despair. Many are treated with antidepressants that take weeks to kick in, and sometimes don't work at all, as they do not address the hormonal changes that happen during and after pregnancy. Each infusion is expected to cost $20,000 to $35,000, NBC News reports, and it's unknown how much insurance will cover. Researchers said each patient will likely only need one infusion. It is expected the FDA will soon decide if the drug is safe for women while breastfeeding.

Read more: https://theweek.com/speedreads/830171/fd...

Similar news

Schwartz Caps Blues' Rally in 3-2 Win Over Jets 1 in Games 5 0 0 0
Maricopa County Is Fastest-Growing US County for 3rd Year 0 0 0
Teen YouTubers fake a pregnancy and then offer a very lame apology — and bad sex ed advice 0 0 0
U.S. looking at ways to hold Zuckerberg accountable 0 0 0
Open Marriage: Husband Turns Transgender 0 0 0
PD releases bodycam footage of pursuit ending in standoff 0 0 0
US wins WTO ruling against China grain import quotas 0 0 0
Nintendo shares surge more than 16% after tie-up with Tencent to sell Switch console in China 0 0 0
Journalist Claims She Was Profiled, Assaulted By Cops, But Bodycam Shows Truth 0 0 0
MLS to Seek Training Compensation, Solidarity Payments for Outgoing Talent 0 0 0